|
Enhanced Ultrasound in Determining Extent of Disease in Women With Primary Breast Cancer Clinical Trials Data presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, calls or treatment using a genuine doctor. We are not docs. Always consult your dr. on Enhanced Ultrasound in Determining Extent of Disease in Women With Primary Breast Cancer conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Enhanced Ultrasound in Determining Extent of Disease in Women With Primary Breast Cancer Clinical research trials and Enhanced Ultrasound in Determining Extent of Disease in Women With Primary Breast Cancer healthcare trials occur in a lot of of places throughout the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the potency of new drugs. The intent of the studies / undertakings is to figure out certain human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector corporations to locate remedies for all kinds of circumstances, including Enhanced Ultrasound in Determining Extent of Disease in Women With Primary Breast Cancer. Enhanced Ultrasound in Determining Extent of Disease in Women With Primary Breast Cancer Clinical Trials and other clinical trials allow volunteers to obtain health treatment alternatives before they are available to the masses. Many times the participants undergo treatment for free, and sometimes they are paid for their time. Occasionally there is a cost for a Enhanced Ultrasound in Determining Extent of Disease in Women With Primary Breast Cancer clinical trial. Participants typically obtain the most effective healthcare available for their Enhanced Ultrasound in Determining Extent of Disease in Women With Primary Breast Cancer condition. Dangers are a reality, nonetheless, and can include extra or frequent mD trips, medical hazards (potentially life-endangering), and/or the treatment being uneffective. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "E" Clinical Trials Conditions > Enhanced Ultrasound in Determining Extent of Disease in Women With Primary Breast Cancer  Enhanced Ultrasound in Determining Extent of Disease in Women With Primary Breast Cancer
Enhanced Ultrasound in Determining Extent of Disease in Women With Primary Breast Cancer
For Condition: stage 3A breast cancer,stage 3B breast cancer,stage 1 breast cancer,stage 2 breast cancer,inflammatory breast cancer
Status: No longer recruiting
Sponsor(s): Royal Marsden NHS Trust ,
Synopsis: RATIONALE: New imaging procedures, such as enhanced ultrasound may improve the ability to determine the extent of breast cancer. PURPOSE: Diagnostic study of enhanced ultrasound in women who have locally advanced primary breast cancer.
Details: OBJECTIVES: I. Measure blood flow of primary breast lesions and corresponding lymph nodes by Power Doppler Ultrasound (PDU) and compare this information with metastatic potential and patient survival in women with primary breast cancer. II. Correlate intratumor/-nodal blood flow with pathological variables using standard histology and special stains in this patient population. III. Correlate intratumor microvessel density with total tumor blood flow and with the presence of axillary lymph node metastases using this diagnostic method in these patients. IV. Correlate tumor blood flow with various markers of angiogenesis using this diagnostic method in these patients. V. Compare tumor blood flow as measured with PDU before and after contrast enhancement in these patients. PROTOCOL OUTLINE: This is a diagnostic study. Patients receive ultrasound contrast agent IV. An ultrasound probe with Power Doppler facility is swept over the skin surface in a standard fashion before and after contrast enhancement. Blood flow data is acquired over the volume of the mass and/or lymph nodes using a video recorder. The scanning time ranges between 5 to 15 minutes depending on the size and exact location of the breast mass and axillary lymph nodes. Within 1 week of the ultrasound, patients undergo surgery and the mass and axillary lymph nodes are removed. PROJECTED ACCRUAL: Approximately 200 patients will be accrued for this study within 1 year.
Eligibility:
Study Type: Interventional, Diagnostic
Minimum Age/Maximum Age: 18 Years/
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Clinically suspected locally advanced breast cancer where treatment indicated is primary surgery (wide local excision or simple mastectomy) and axillary dissection (clearance) - Inflammatory breast cancer eligible - No recurrent disease - Hormone receptor status: Not specified --Prior/Concurrent Therapy-- - Biologic therapy: Not specified - Chemotherapy: No prior neoadjuvant chemotherapy - Endocrine therapy: Not specified - Radiotherapy: Not specified - Surgery: See Disease Characteristics; At least 1 month since prior core biopsy (Tru-cut) of breast cancer --Patient Characteristics-- - Age: 18 and over - Sex: Female - Menopausal status: Not specified - Performance status: Not specified - Life expectancy: Not specified - Hematopoietic: Not specified - Hepatic: Not specified - Renal: Not specified - Cardiovascular: No New York Heart Association class III or IV heart disease; At least 14 days since prior myocardial infarction - Pulmonary: No severe chronic obstructive pulmonary disease - Other: No galactosemia; No mental illness or handicap
Total Enrollment:
Location and Contact Information:
Overall Study Official:
GeraldGui, Study Chair, Royal Marsden NHS Trust
Royal Marsden NHS Trust
London, England, SW3 6JJ
United Kingdom
Additional Information:
Study ID Numbers: CDR0000067655; RMNHS-1443,EU-20003
Study Start Date: August 1997
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00005058
Other Stage 1 Breast Cancer Studies:
1. MRI-Guided Ultrasound Energy in Treating Patients With Stage I, Stage II, or Stage IIIA Breast Cancer
2. Radiation Therapy After Surgery in Treating Women With Early Stage Breast Cancer
3. Epoetin Alfa in Treating Chemotherapy-Related Anemia in Women With Stage I, Stage II, or Stage III Breast Cancer
4. Study of Health Promotion in Patients With Early-Stage Breast or Prostate Cancer
5. Cryosurgery in Treating Women With Breast Lesions
Related Studies:
Other stage 1 breast cancer Clinical Trials
Other England Clinical Trials
Other London Clinical Trials
Enhanced Ultrasound in Determining Extent of Disease in Women With Primary Breast Cancer
|
|
|
|
|
|
|
|
